PSMA PET for the Staging and Management of Hepatocellular Carcinoma
Recruiting
Observational Study
Hepatocellular Carcinoma (HCC)
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 90 (estimated)
- Sponsor
- VA Office of Research and Development · Federal
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This prospective, single-center study evaluates the clinical utility of F18-Piflufolastat (PSMA) PET/CT when added to conventional cross-sectional imaging for patients with suspected or confirmed hepatocellular carcinoma (HCC). The study aims to determine whether PSMA PET/CT improves diagnostic accuracy for indeterminate liver lesions (LI-RADS 3 and 4), enhances staging precision in treatment-naïv…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Adult patients age \>18 years from the VA medical system
* Treatment-naïve patients with HCC with BCLC B or C disease
Exclusion Criteria:
* Patients with renal dysfunction or contrast allergy that precludes contrast enhanced cross sectional imaging
* Patients with presence o…
Contacts